Chris Savile, Chief Operating Officer at Willow Biosciences
Chapters:
0:00 CBG vs CBD
5:20 More pure, cheaper going the synthetic biology route
11:20 New CRISPR whole genome editing tools enabling scale
14:06 What scale are you at?
18:43 What are the first markets of interest?
We see this new ingredient appearing advertised and in products everywhere. On the billboards, in the new shops next to our favorite restaurant, on the counters at the barbershop and when we pick up our prescriptions at the pharmacy.
C-B-D.
It has to do with the ongoing revolution that’s happening around the country—around the world—regarding the deregulation of marijuana. But there’s another revolution that will change our consumption of cannabinoids. That of synthetic biology.
Biologists, chemists, and engineers will be providing us CBD in more pure and larger quantities at a much cheaper price synthetically than farmers will. It will come in many of the products we use, including nutraceuticals, personal care products, and pharmaceuticals.
Chris Savile joins us today. He’s the Chief Operating Officer at Willow Biosciences, a Canadian biotech company that began producing it’s first synthetic cannabinoid earlier this month. Interestingly, it is not CBD, but rather CBG or cannabigerol. Did you know there are over a hundred cannabinoids, and CBG cannot be isolated by traditionally farming?
Join us to learn how new CRISPR based whole genome editing tools are enabling a new industry to develop.
